1 Alcohol Use Disorders Unit, Department of Internal Medicine, Gastroenterology and Hepatology, Catholic University of Rome, Rome, Italy.2 Liver Center, Division of Gastroenterology and Hepatology, Departments of Medicine and Nutrition, University of North Carolina, Chapel Hill, NC.3 Multivisceral Transplant Unit, Gastroenterology Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy.4 Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.5 Department of Internal Medicine II, Medical University of Innsbruck & Academic Teaching Hospital Hall, Innsbruck, Austria.6 Department of Internal Medicine, Academic Teaching Hospital Hall, Austria.7 Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, WI.8 Service des Maladies de l'Appareil Digestif, Hôpital Huriez, Lille, France.9 Liver Unit, King's College Hospital, London, United Kingdom.10 Département d'Hépatogastroenterologie et Transplantation, CHU Saint Eloi, Université de Montpellier, Montpellier, France.11 Liver Transplantation and Hepatology Unit, La Fe University Hospital, Ciberehd and Valencia University, Valencia, Spain.12 Ciberehd, University of Valencia, Valencia, Spain.
Checking for direct PDF access through Ovid
Alcohol-related liver disease is the second most frequent indication for liver transplantation (LT), yet as many as 90% to 95% of patients with alcohol-related end-stage liver disease are never formally evaluated for LT. Furthermore, despite its significance as a cause of chronic liver disease and indication for LT, it has received little attention in recent years for several reasons, including the good posttransplant short-term results, and the lack of specific “drugs” used for this disease. A writing group, endorsed by the International Liver Transplant Society, was convened to write guidelines on Liver Transplantation for Alcoholic Liver Disease to summarize current knowledge and provide answers to controversial and delicate ethical as well as clinical problems. We report here a short version of the guidelines (long version available at www.ilts.org) with the final recommendations graded for level of evidence. The writing group membership is expected to remain active for 5 years, reviewing the guideline annually, and updating the online version when appropriate.